123 related articles for article (PubMed ID: 8382870)
21. Passive immunization against cytomegalovirus during pregnancy.
Silverman NS; Puliyanda D; Lehman D
N Engl J Med; 2005 Dec; 353(26):2818-20; author reply 2818-20. PubMed ID: 16382073
[No Abstract] [Full Text] [Related]
22. Treatment of CMV infections and disease in transplantation.
Schmidt GM
Transplant Proc; 1991 Jun; 23(3 Suppl 3):126-9, discussion 129-30. PubMed ID: 1648816
[No Abstract] [Full Text] [Related]
23. Prophylactic immunoglobulin therapy improves the outcome of renal transplantation in recipients at risk for primary cytomegalovirus disease.
Conti DJ; Freed BM; Lempert N
Transplant Proc; 1993 Feb; 25(1 Pt 2):1421-2. PubMed ID: 8382867
[No Abstract] [Full Text] [Related]
24. Combination antiviral strategies in managing cytomegalovirus infection.
Martin M
Transplant Proc; 1994 Oct; 26(5 Suppl 1):28-30. PubMed ID: 7940973
[No Abstract] [Full Text] [Related]
25. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients.
Ahsan N; Holman MJ; Yang HC
Clin Transplant; 1997 Dec; 11(6):633-9. PubMed ID: 9408699
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of cytomegalovirus prophylaxis in renal retransplantation.
Singh TP; Gruber SA; Lempert N; Freed B; Conti DJ
Transplant Proc; 1995 Feb; 27(1):964-5. PubMed ID: 7879247
[No Abstract] [Full Text] [Related]
27. Use of intravenous immunoglobulin prophylaxis for primary cytomegalovirus infection post living-related-donor renal transplantation.
Steinmuller DR; Graneto D; Swift C; Novick AC; Streem SB; Cunningham RJ; Hodge E; Bretan P
Transplant Proc; 1989 Feb; 21(1 Pt 2):2069-71. PubMed ID: 2540554
[No Abstract] [Full Text] [Related]
28. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L;
Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
[TBL] [Abstract][Full Text] [Related]
29. Cytomegalovirus infection in kidney transplantation: prophylaxis and management.
Bulinski P; Toledo-Pereyra LH; Dalal S; Hernandez G
Transplant Proc; 1996 Dec; 28(6):3310-1. PubMed ID: 8962286
[No Abstract] [Full Text] [Related]
30. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.
Razonable RR; Rivero A; Rodriguez A; Wilson J; Daniels J; Jenkins G; Larson T; Hellinger WC; Spivey JR; Paya CV
J Infect Dis; 2001 Dec; 184(11):1461-4. PubMed ID: 11709790
[TBL] [Abstract][Full Text] [Related]
31. Ganciclovir prophylaxis delays but does not prevent cytomegalovirus infection in renal transplant recipients.
Israni A; Krok K; Cohen D; Blumberg E; Bloom RD
Transplant Proc; 2004 Dec; 36(10):3019-24. PubMed ID: 15686685
[TBL] [Abstract][Full Text] [Related]
32. Impact of ganciclovir prophylaxis on heart-lung and lung transplant recipients.
Soghikian MV; Valentine VG; Berry GJ; Patel HR; Robbins RC; Theodore J
J Heart Lung Transplant; 1996 Sep; 15(9):881-7. PubMed ID: 8889983
[TBL] [Abstract][Full Text] [Related]
33. Prospective study of the incidence, timing, significance, risk factors, and outcome of cytomegalovirus infection in liver transplant patients with double-drug immunosuppression and no prophylactic antiviral therapy.
Sanchez-Turrión V; Cuervas-Mons V; Portero F; Barrios C; Garrido A; Albillos A
Transplant Proc; 1993 Apr; 25(2):1786. PubMed ID: 8385824
[No Abstract] [Full Text] [Related]
34. Ganciclovir for cytomegalovirus: a call for indefinite prophylaxis in lung transplantation.
Valentine VG; Weill D; Gupta MR; Raper B; Laplace SG; Lombard GA; Bonvillain RW; Taylor DE; Dhillon GS
J Heart Lung Transplant; 2008 Aug; 27(8):875-81. PubMed ID: 18656801
[TBL] [Abstract][Full Text] [Related]
35. Reactivation of CMV in human lung transplants.
Behrend M; Steinhoff G; Wagner TO; Haverich A
Transplant Proc; 1990 Aug; 22(4):1822-3. PubMed ID: 2167541
[No Abstract] [Full Text] [Related]
36. Randomized trial of daily versus three-times-weekly prophylactic ganciclovir after lung and heart-lung transplantation.
Hertz MI; Jordan C; Savik SK; Fox JM; Park S; Bolman RM; Dosland-Mullan BM
J Heart Lung Transplant; 1998 Sep; 17(9):913-20. PubMed ID: 9773865
[TBL] [Abstract][Full Text] [Related]
37. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ
Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289
[TBL] [Abstract][Full Text] [Related]
38. Cytomegalovirus hyperimmunoglobulin prophylaxis in the prevention of cytomegalovirus infection in immunosuppressed heart transplant patients.
Havel M; Teufelsbauer H; Laczkovics A; Kurz R; Wolner E
Transplant Proc; 1990 Aug; 22(4):1805-6. PubMed ID: 2167533
[No Abstract] [Full Text] [Related]
39. The usefulness of hyperimmune globulin for treatment of overt cytomegalovirus infection in allograft recipients.
Rancewicz Z; Halama G; Smogorzewski M; Durlik M; Rowinska D; Lao M; Juskowa J; Wyzgal J
Transplant Proc; 1990 Aug; 22(4):1818-9. PubMed ID: 2167538
[No Abstract] [Full Text] [Related]
40. Extended ganciclovir prophylaxis in lung transplantation.
Perreas KG; McNeil K; Charman S; Sharples LD; Wreghitt T; Wallwork J
J Heart Lung Transplant; 2005 May; 24(5):583-7. PubMed ID: 15896756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
